Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19207094 | LEPTIN COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME TO SUPPORT WEIGHT LOSS AND/OR MAINTENANCE | May 2025 | September 2025 | Allow | 5 | 1 | 1 | No | No |
| 19192339 | ANTIMICROBIAL PEPTIDE AND APPLICATION THEREOF | April 2025 | February 2026 | Abandon | 10 | 0 | 1 | No | No |
| 19172886 | PAM3CSK4 INJECTION FOR THE PREVENTION AND MANAGEMENT OF MASLD | April 2025 | October 2025 | Allow | 6 | 0 | 1 | Yes | No |
| 19024178 | FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION | January 2025 | October 2025 | Abandon | 9 | 0 | 1 | No | No |
| 18853789 | Treatment for Ocular Fibrosis | October 2024 | July 2025 | Allow | 10 | 0 | 1 | No | No |
| 18903864 | THERAPEUTIC POLYPEPTIDE | October 2024 | April 2025 | Allow | 6 | 0 | 1 | No | No |
| 18893357 | INCRETIN ANALOGS AND USES THEREOF | September 2024 | March 2025 | Allow | 6 | 1 | 1 | No | No |
| 18829844 | PEPTIDE COMPOSITIONS CAPABLE OF BINDING LANTHIONINE SYNTHETASE C-LIKE PROTEIN (LANCL) AND USES THEREOF | September 2024 | August 2025 | Allow | 11 | 1 | 1 | No | No |
| 18806394 | PROCESSES AND INTERMEDIATES FOR PREPARING TIRZEPATIDE | August 2024 | February 2025 | Allow | 6 | 0 | 1 | No | No |
| 18834531 | Recombinant Humanized Collagen Type III Alpha-1, and Expression Vector and Use Thereof | July 2024 | January 2026 | Allow | 18 | 1 | 1 | No | No |
| 18697004 | TRICYCLIC POLYPEPTIDE CONJUGATED DRUG AND USE THEREOF | March 2024 | October 2025 | Allow | 19 | 0 | 1 | No | No |
| 18611711 | GENE PPARalpha FOR IMPROVING DISEASE RESISTANCE OF HALF-SMOOTH TONGUE SOLE CYNOGLOSSUS SEMILAEVIS AND USE THEREOF | March 2024 | September 2025 | Abandon | 18 | 1 | 1 | No | No |
| 18612627 | HUMAN COLLAGEN 17-TYPE POLYPEPTIDE, PRODUCTION METHOD THEREFOR AND USE THEREOF | March 2024 | June 2025 | Allow | 14 | 1 | 1 | No | No |
| 18612612 | HUMAN COLLAGEN 17-TYPE POLYPEPTIDE, PRODUCTION METHOD THEREFOR AND USE THEREOF | March 2024 | June 2025 | Allow | 14 | 1 | 1 | No | No |
| 18601031 | COMPSTATIN ANALOGUES AND THEIR MEDICAL USES | March 2024 | December 2025 | Allow | 21 | 1 | 1 | No | No |
| 18584321 | PEPTIDE USED FOR IMMUNOTHERAPEUTICS | February 2024 | July 2025 | Allow | 17 | 2 | 1 | Yes | No |
| 18444501 | Compositions comprising pharmaceutically acceptable salts of glucagon-like peptide-1 analogs and pharmaceutically acceptable salts of amylin analogs, and uses thereof | February 2024 | October 2024 | Allow | 8 | 0 | 1 | No | No |
| 18424386 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEX | January 2024 | March 2025 | Allow | 13 | 0 | 0 | No | No |
| 18420332 | Treatment of Ascites | January 2024 | September 2025 | Abandon | 20 | 2 | 1 | No | Yes |
| 18578613 | SELF-ASSEMBLING PEPTIDE AMPHIPHILES DISPLAYING A TRANSFORMING GROWTH FACTOR BETA 1 (TGF-ß1) MIMETIC EPITOPE | January 2024 | December 2025 | Allow | 23 | 2 | 1 | No | No |
| 18390354 | MOLECULAR GUIDE SYSTEM PEPTIDES AND USES THEREOF | December 2023 | June 2025 | Allow | 18 | 2 | 1 | No | No |
| 18568525 | Peptide compounds targeting PD-1 receptor as well as preparation and applications thereof | December 2023 | January 2025 | Allow | 14 | 1 | 1 | No | No |
| 18524461 | COMPOSITIONS AND METHODS FOR TREATING ENDOMETRIOSIS | November 2023 | July 2025 | Allow | 19 | 0 | 1 | No | No |
| 18492982 | VSIG8-BASED CHIMERIC PROTEINS | October 2023 | May 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18491750 | Interference Peptides As Inhibitors Of Interactions Related To Ampar Endocytosis | October 2023 | January 2025 | Abandon | 15 | 0 | 1 | No | No |
| 18483108 | POLYPEPTIDES AND MEDICAL USES THEREOF | October 2023 | June 2024 | Allow | 9 | 0 | 1 | No | No |
| 18554481 | PEPTIDE FOR PREVENTING OR TREATING INFLAMMATORY DISEASES | October 2023 | March 2026 | Allow | 29 | 0 | 0 | No | No |
| 18473073 | PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION | September 2023 | September 2024 | Allow | 12 | 1 | 1 | No | No |
| 18467206 | FUSION PROTEIN COMPOSITION(S) COMPRISING MASKED TYPE I INTERFERONS (IFNA AND IFNB) FOR USE IN THE TREATMENT OF CANCER AND METHODS THEREOF | September 2023 | August 2024 | Allow | 11 | 0 | 1 | No | No |
| 18550098 | Composition for Treatment and/or Prevention of a Corona Virus Infection | September 2023 | February 2026 | Allow | 29 | 0 | 0 | No | No |
| 18549552 | METHOD OF CLARIFYING A CRUDE PROTEIN SOLUTION | September 2023 | February 2026 | Allow | 29 | 0 | 0 | No | No |
| 18242653 | PEPTIDE USED FOR IMMUNOTHERAPEUTICS | September 2023 | March 2026 | Allow | 30 | 0 | 0 | No | No |
| 18548832 | METHODS FOR CYCLIZATION OF (POLY)PEPTIDES COMPRISING Ny-HYDROXY- OR Ny-AMINO-L-ASPARAGINE | September 2023 | February 2026 | Allow | 29 | 0 | 0 | No | No |
| 18460300 | PEPTIDE-COMPOUND CYCLIZATION METHOD | September 2023 | March 2025 | Allow | 19 | 1 | 1 | No | No |
| 18446172 | PEPTIDES AND METHODS FOR THE TREATMENT OF DIABETES | August 2023 | December 2025 | Allow | 29 | 1 | 1 | No | No |
| 18366558 | CONJUGATED HEPCIDIN MIMETICS | August 2023 | October 2024 | Allow | 14 | 0 | 1 | No | No |
| 18274952 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERS | July 2023 | May 2025 | Allow | 21 | 4 | 0 | No | No |
| 18333628 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | June 2023 | January 2026 | Allow | 31 | 0 | 0 | No | No |
| 18317017 | Polypeptide Integrin Antagonists | May 2023 | October 2024 | Abandon | 17 | 0 | 1 | No | No |
| 18311049 | MODIFIED VASOACTIVE INTESTINAL PEPTIDES | May 2023 | January 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18306911 | RECOMBINANT CDHR3 PROTEIN FRAGMENTS INHIBIT RHINOVIRUS C BINDING AND REPLICATION | April 2023 | June 2025 | Allow | 25 | 1 | 1 | No | No |
| 18304159 | GELATIN PARTICLES, METHOD FOR PRODUCING GELATIN PARTICLES, GELATIN PARTICLE-CONTAINING CELL, AND METHOD FOR PRODUCING GELATIN PARTICLE-CONTAINING CELL | April 2023 | August 2025 | Allow | 28 | 2 | 1 | No | No |
| 18031978 | GLP-1/GIP DUAL AGONIST, LONG-ACTING CONJUGATE THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | April 2023 | November 2025 | Allow | 31 | 0 | 0 | No | No |
| 18031762 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | April 2023 | November 2025 | Allow | 31 | 0 | 0 | No | No |
| 18130764 | INHIBITION OF TREM RECEPTOR SIGNALING WITH PEPTIDE VARIANTS | April 2023 | August 2024 | Allow | 16 | 1 | 1 | No | No |
| 18030171 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | April 2023 | November 2025 | Allow | 31 | 0 | 1 | No | No |
| 18182726 | SELF-ASSEMBLY OF PROTEIN-BASED BIOMATERIALS WITH MULTIPLE MORPHOLOGIES | March 2023 | December 2024 | Allow | 21 | 2 | 1 | No | No |
| 18119920 | ENGINEERED SEMAPHORINS AND USES THEREOF | March 2023 | August 2024 | Abandon | 17 | 0 | 1 | No | No |
| 18118587 | AUTOLOGOUS AND ALLOGENIC HIV-1 PROTEINS FOR THE TREATMENT OF LATENT HIV-1 INFECTION | March 2023 | July 2025 | Allow | 29 | 1 | 1 | No | No |
| 18116331 | COOKED MILLET PROLAMIN PEPTIDE FOR INHIBITING ALPHA-AMYLASE AND ALPHA-GLUCOSIDASE | March 2023 | February 2024 | Allow | 11 | 1 | 1 | Yes | No |
| 18169971 | COMPOSITIONS AND METHODS FOR BLOCKING ULTRAVIOLET RADIATION | February 2023 | March 2024 | Allow | 13 | 1 | 1 | No | No |
| 18165986 | COMPOUNDS AND METHODS FOR TREATING TIGHT JUNCTION PERMEABILITY | February 2023 | April 2024 | Abandon | 14 | 0 | 1 | No | No |
| 18104643 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | February 2023 | February 2025 | Allow | 24 | 1 | 1 | No | No |
| 18153973 | AN IMMUNOMODULATORY PROTEIN FOR ALLEVIATION AND/OR TREATMENT OF CORONAVIRUS DISEASES | January 2023 | August 2024 | Allow | 19 | 1 | 1 | No | No |
| 18150680 | Interference Peptides As Inhibitors Of Interactions Related To Ampar Endocytosis | January 2023 | August 2023 | Allow | 8 | 1 | 1 | No | No |
| 18013344 | POLYPEPTIDE FOR REPAIRING MUCOSAL DAMAGE OR SKIN WOUND AND USE THEREOF | December 2022 | May 2025 | Allow | 28 | 1 | 2 | No | No |
| 18069797 | MODULATING ANGIOGENESIS BY PROTEOMIMETICS OF VASCULAR ENDOTHELIAL GROWTH FACTOR | December 2022 | October 2023 | Allow | 10 | 0 | 1 | No | No |
| 18011155 | INHALATION FORMULATIONS OF ANTIMICROBIAL COMPOUNDS | December 2022 | August 2025 | Allow | 32 | 0 | 0 | No | No |
| 18081964 | HYDROGEL FOR CELL-LADEN BIOPRINTING, BIOINK, AND PREPARATION METHOD AND APPLICATION THEREOF | December 2022 | July 2025 | Allow | 31 | 0 | 0 | No | No |
| 18061735 | IL-2RGAMMA BINDING COMPOUNDS | December 2022 | October 2024 | Abandon | 22 | 1 | 1 | No | No |
| 18008034 | PHARMACEUTICAL COMPOSITION FOR ENHANCING RADIOTHERAPY COMPRISING FUSION PROTEIN CONTAINING IL-2 PROTEIN AND CD80 PROTEIN | December 2022 | July 2025 | Allow | 32 | 0 | 0 | No | No |
| 18058134 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | November 2022 | December 2025 | Abandon | 37 | 3 | 1 | No | No |
| 17995992 | PREVENTION AND TREATMENT OF ORGAN INJURIES | October 2022 | June 2025 | Allow | 32 | 0 | 0 | No | No |
| 17917391 | BIOLOGICAL FUNCTION REGULATING AGENT, EPIDERMAL METABOLISM PROMOTING AGENT, FAT ACCUMULATION INHIBITING AGENT, FAT DECOMPOSITION PROMOTING AGENT, ADIPONECTIN PRODUCTION PROMOTING AGENT, FUNCTIONAL FOOD, COSMETIC PRODUCT, AND METHOD FOR PRODUCING BIOLOGICAL FUNCTION REGULATING AGENT | October 2022 | June 2025 | Allow | 32 | 0 | 0 | No | No |
| 17958959 | COLLAGEN COMPOSITIONS AND METHODS OF USE | October 2022 | September 2024 | Allow | 23 | 2 | 1 | No | No |
| 17935862 | Small Molecule Cancer Treatments that Cause Necrosis in Cancer Cells But Do Not Affect Normal Cells | September 2022 | May 2024 | Abandon | 20 | 0 | 1 | No | No |
| 17914603 | METHODS AND COMPOSITIONS | September 2022 | June 2025 | Allow | 32 | 0 | 0 | No | No |
| 17908258 | RECOMBINANT HUMAN TYPE XVII COLLAGEN, AND PREPARATION METHOD AND USE THEREOF | August 2022 | July 2023 | Allow | 11 | 1 | 1 | No | No |
| 17823180 | PEPTIDE USED FOR IMMUNOTHERAPEUTICS | August 2022 | December 2023 | Allow | 15 | 2 | 1 | Yes | No |
| 17641539 | APPLICATION OF NON-IGF1R-BINDING SUBSTANCE IN PREVENTION AND/OR TREATMENT OF INFLAMMATORY DISEASES | August 2022 | February 2026 | Abandon | 47 | 0 | 1 | No | No |
| 17800818 | MOLECULES TARGETING RAS PROTEIN | August 2022 | February 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17865438 | NOVEL FATTY ACID MODIFIED UROCORTIN 2 DERIVATIVES AND THE USES THEREOF | July 2022 | July 2023 | Abandon | 12 | 0 | 1 | No | No |
| 17811848 | PEPTIDE TARGETING MYCOBACTERIUM TUBERCULOSIS TOXIN-ANTITOXIN SYSTEM AND USE THEREOF | July 2022 | July 2023 | Allow | 12 | 0 | 1 | No | No |
| 17855305 | PLATFORMS, COMPOSITIONS, AND METHODS FOR THERAPEUTIC DELIVERY | June 2022 | August 2023 | Allow | 14 | 1 | 1 | Yes | No |
| 17854190 | PEPTIDES AND METHODS FOR THE TREATMENT OF DIABETES | June 2022 | May 2023 | Allow | 10 | 0 | 1 | No | No |
| 17844647 | METHODS OF TREATING NEUROLOGICAL DISEASES | June 2022 | January 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17806834 | USE OF CGRP RECEPTOR ANTAGONISTS IN NEUROPROTECTION AND NEUROLOGICAL DISORDERS | June 2022 | June 2024 | Allow | 24 | 1 | 1 | No | No |
| 17635561 | METAL-BINDING PEPTIDE, AND USE THEREOF | June 2022 | January 2026 | Abandon | 47 | 0 | 1 | No | No |
| 17831556 | Treatment of Ascites | June 2022 | May 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17749004 | MODIFICATIONS OF PEPTIDE COMPOSITIONS TO INCREASE STABILITY AND DELIVERY EFFICIENCY | May 2022 | March 2024 | Abandon | 22 | 1 | 1 | No | No |
| 17777227 | NANOPARTICLE-LIKE DELIVERY SYSTEM | May 2022 | September 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17741020 | IL-2RBETA BINDING COMPOUNDS | May 2022 | August 2024 | Abandon | 27 | 2 | 1 | No | No |
| 17774873 | TUMOR-SPECIFIC POLYPEPTIDE SEQUENCE AND USE THEREOF | May 2022 | November 2025 | Allow | 42 | 1 | 1 | No | No |
| 17738572 | ANTIMICROBIAL PEPTIDES AND METHODS OF USING SAME | May 2022 | March 2024 | Allow | 23 | 0 | 2 | No | No |
| 17737058 | POLYPEPTIDE FRAGMENT B (MP-B) AND USE THEREOF | May 2022 | June 2025 | Allow | 37 | 0 | 1 | No | No |
| 17737862 | PEPTIDE-LIPID CONJUGATES | May 2022 | February 2026 | Allow | 45 | 0 | 1 | No | No |
| 17719074 | COMBINATION THERAPY FOR C3 INHIBITION | April 2022 | July 2025 | Abandon | 39 | 0 | 2 | No | No |
| 17767403 | POLYPEPTIDE HAVING ANTI-AGING ACTIVITY, AND APPLICATION THEREOF | April 2022 | July 2025 | Allow | 39 | 1 | 1 | No | No |
| 17761992 | HUMAN COLLAGEN 17-TYPE POLYPEPTIDE, PRODUCTION METHOD THEREFOR AND USE THEREOF | March 2022 | May 2024 | Allow | 26 | 1 | 1 | No | No |
| 17695363 | METHODS FOR TREATING PSYCHIATRIC DISORDERS OR SYMPTOMS THEREOF USING NCAM PEPTIDE MIMETICS | March 2022 | June 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17642764 | NEW PEPTIDES | March 2022 | December 2025 | Allow | 45 | 1 | 1 | No | No |
| 17694478 | pH-SENSITIVE CYCLIC PEPTIDES | March 2022 | June 2025 | Abandon | 39 | 1 | 1 | No | No |
| 17654226 | NEUROTOXINS FOR USE IN INHIBITING CGRP | March 2022 | July 2023 | Abandon | 16 | 0 | 1 | No | No |
| 17687029 | COMPOSITIONS AND METHODS OF INHIBITING THE BINDING OF PLASMA IGG AUTOANTIBODIES TO SEROTONIN 2A RECEPTOR | March 2022 | June 2024 | Allow | 27 | 3 | 1 | Yes | No |
| 17639547 | A PEPTIDE USED FOR IMMUNOTHERAPEUTICS | March 2022 | November 2025 | Abandon | 44 | 2 | 1 | No | No |
| 17672412 | PEPTIDE NANOPARTICLES AND USES THEREFOR | February 2022 | February 2023 | Abandon | 12 | 1 | 1 | Yes | No |
| 17634466 | THERAPEUTIC PEPTIDES | February 2022 | October 2024 | Allow | 32 | 0 | 0 | No | No |
| 17592966 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEX | February 2022 | October 2023 | Allow | 20 | 1 | 1 | No | No |
| 17632463 | MELANOCYTE-REGULATING PEPTIDES | February 2022 | September 2025 | Allow | 43 | 1 | 1 | No | No |
| 17580692 | COMPOSITIONS FOR TREATING HEART DISEASE BY INHIBITING THE ACTION OF mAKAP-beta | January 2022 | November 2023 | Allow | 21 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner STEELE, AMBER D.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 10.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner STEELE, AMBER D works in Art Unit 1658 and has examined 424 patent applications in our dataset. With an allowance rate of 63.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 28 months.
Examiner STEELE, AMBER D's allowance rate of 63.2% places them in the 23% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by STEELE, AMBER D receive 1.65 office actions before reaching final disposition. This places the examiner in the 33% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by STEELE, AMBER D is 28 months. This places the examiner in the 67% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +13.7% benefit to allowance rate for applications examined by STEELE, AMBER D. This interview benefit is in the 51% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 26.0% of applications are subsequently allowed. This success rate is in the 42% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 37.6% of cases where such amendments are filed. This entry rate is in the 57% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 57.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 48% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 53.8% of appeals filed. This is in the 25% percentile among all examiners. Of these withdrawals, 57.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 75.0% are granted (fully or in part). This grant rate is in the 80% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.